1. Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn’s Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells
   Dominika Kovács et al, 2021, Oxidative Medicine and Cellular Longevity CrossRef
2. Paris polyphylla extract attenuates colitis in mice by regulating PPAR-γ mediated Treg/Th17 balance
   Long He et al, 2023, Journal of Ethnopharmacology CrossRef
3. Epithelial NAD+ depletion drives mitochondrial dysfunction and contributes to intestinal inflammation
   Elizabeth A. Novak et al, 2023, Frontiers in Immunology CrossRef
4. CD38: An important regulator of T cell function
   Wentao Li et al, 2022, Biomedicine & Pharmacotherapy CrossRef
5. Stanniocalcin‐1 Promotes PARP1‐Dependent Cell Death via JNK Activation in Colitis
   Liguo Zhu et al, 2024, Advanced Science CrossRef
6. Research progress of phenolic compounds regulating IL‐6 to exert antitumor effects
   Tingting Xia et al, 2021, Phytotherapy Research CrossRef
7. 3-aminobenzamide protects against colitis associated diabetes mellitus in male BALB/c mice: Role of PARP-1, NLRP3, SIRT-1, AMPK
   Shivani Singla et al, 2023, Biochimie CrossRef
8. Shaoyao decoction alleviates TNBS-induced ulcerative colitis by decreasing inflammation and balancing the homeostasis of Th17/Treg cells
   Dongsheng Wu et al, 2023, BMC Complementary Medicine and Therapies CrossRef
9. Quantitative Determination of 5-Aminoisoquinoline, a PARP-1 Inhibitor by UPLC-MS/MS: In Silico ADME Profile and In Vitro Metabolic Stability Study
   Muzaffar Iqbal et al, 2022, Applied Sciences CrossRef